§ 01
What Are Corticosteroids?
Corticosteroids Treatment
Overview DiagramCorticosteroids — also referred to as glucocorticoids in this therapeutic context — are synthetic analogues of cortisol, the endogenous steroid hormone produced by the adrenal cortex. Cortisol is the body’s main endogenous anti-inflammatory and immunomodulatory hormone. Synthetic corticosteroids have been engineered to amplify the glucocorticoid effect while minimizing mineralocorticoid activity, which is the part more associated with salt retention and blood-pressure effects.
The distinction between glucocorticoid and mineralocorticoid activity is relevant to drug selection. Glucocorticoid activity mediates anti-inflammatory and immunomodulatory effects through the glucocorticoid receptor. Mineralocorticoid activity is generally less desirable in most soft-tissue injection settings. Modern injectables such as triamcinolone, dexamethasone, and betamethasone are therefore chosen primarily for glucocorticoid potency with relatively little mineralocorticoid activity.
In myofascial pain syndrome, corticosteroids are injected directly into or adjacent to selected trigger points when the clinician believes local inflammatory activity is meaningfully contributing to pain. The goal is targeted local anti-inflammatory treatment rather than systemic therapy. In practice, this approach makes the most sense when a trigger point seems especially reactive or inflamed rather than when the pain appears purely mechanical, motor-endplate-driven, or centrally amplified.
Corticosteroids are powerful anti-inflammatory tools, but their role in myofascial pain is more selective and limited than in some other conditions.
Corticosteroid trigger point injection is not appropriate for every trigger point. Repeat injections at the same site can cause cumulative local tissue damage including subcutaneous atrophy, fat necrosis, skin depigmentation, and tendon weakening. For that reason, this is usually a selective and use-limited tool rather than a routine repeat strategy.
§ 02
Mechanisms of Action
Mechanisms of Action
Mechanism DiagramPhospholipase A2 Inhibition
Corticosteroids induce synthesis of lipocortin-1 (annexin A1), a protein that inhibits phospholipase A2. This is an upstream anti-inflammatory effect — phospholipase A2 is the enzyme that cleaves arachidonic acid from membrane phospholipids. By suppressing this step, corticosteroids reduce downstream synthesis of both prostaglandins (via the COX pathway) and leukotrienes (via the LOX pathway). This broader pathway effect is one reason corticosteroids are often described as more wide-ranging anti-inflammatory agents than NSAIDs, which primarily affect the COX pathway.
NF-kB Pathway Suppression
Nuclear factor kappa-B (NF-kB) is a major transcription factor involved in the expression of many pro-inflammatory genes. Corticosteroids suppress NF-kB through multiple mechanisms, including upregulating IkB-alpha, interfering with NF-kB DNA binding, and competing for transcriptional coactivators. This is generally considered one of the core genomic anti-inflammatory mechanisms behind corticosteroid action.
Pro-Inflammatory Cytokine Downregulation
Corticosteroids reduce production of key pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. In trigger point practice, this mechanism is most relevant when there appears to be a meaningful inflammatory component around an active pain generator. Reducing local cytokine signaling may help lessen nociceptor sensitization and local tissue irritability in selected cases.
Leukocyte Migration Inhibition
Corticosteroids reduce expression of adhesion molecules on vascular endothelial cells and suppress chemokine signaling, thereby limiting migration of inflammatory cells into tissue. In practical terms, this is part of how they reduce local inflammatory activity, edema, and immune-cell recruitment at an irritated site.
Peripheral Nociceptor Desensitization
Beyond broad anti-inflammatory effects, corticosteroids may also influence peripheral nociceptor sensitivity. They are discussed as reducing expression of pronociceptive ion channels and lowering levels of local mediators such as NGF, BDNF, and substance P. The clinical relevance of this likely varies, but it helps explain why corticosteroid injections may sometimes reduce pain beyond simple anti-inflammatory suppression alone.
Genomic vs Non-Genomic Effects
Corticosteroid effects are often divided into genomic and non-genomic mechanisms. Genomic effects involve glucocorticoid receptor signaling and altered gene transcription, which helps explain why some benefits develop over hours rather than instantly. Non-genomic effects may occur more quickly through membrane-level and vascular effects. Both pathways likely contribute to the overall clinical response.
§ 03
Drug Profiles
Triamcinolone Acetonide
Common Trigger Point SteroidKenalog
Concentration10 mg/mL or 40 mg/mL
Onset24–48 hours
Duration2–6 weeks
Atrophy RiskModerate to High
One of the most commonly used corticosteroids for trigger point injection. Triamcinolone acetonide is a fluorinated synthetic glucocorticoid formulated as an aqueous microcrystalline suspension. Its depot characteristics result in slower local absorption and potentially longer local effect. Lower concentrations are often preferred for more superficial sites to reduce atrophy risk, while higher concentrations may be considered in deeper muscular injections. It has negligible mineralocorticoid activity.
Methylprednisolone Acetate
Widely AvailableDepo-Medrol
Concentration20 mg/mL, 40 mg/mL, or 80 mg/mL
Onset24–48 hours
Duration2–4 weeks
Atrophy RiskModerate
Methylprednisolone acetate is a non-fluorinated synthetic glucocorticoid depot preparation with anti-inflammatory potency broadly comparable to triamcinolone. It is widely used for soft-tissue and joint injections. Some clinicians prefer it over triamcinolone in certain superficial areas because it may carry a somewhat lower risk of visible atrophy or depigmentation, though comparative data are limited.
Dexamethasone Sodium Phosphate
Lower Atrophy RiskDecadron
Concentration4 mg/mL
Onset1–3 hours (rapid)
Duration3–7 days
Atrophy RiskLow
Dexamethasone sodium phosphate is a highly potent, soluble corticosteroid that is more rapidly absorbed from the injection site. Because it does not form the same crystal depot as triamcinolone or methylprednisolone, it is often considered when lower local atrophy risk is desired, especially in more superficial or cosmetically sensitive areas. The tradeoff is a potentially shorter local duration of effect.
Betamethasone (Celestone Soluspan)
Dual-Phase ActionCelestone Soluspan
Concentration6 mg/mL (3 mg acetate + 3 mg sodium phosphate)
Onset1–3 hours (soluble fraction); 24–48 hours (depot fraction)
Duration2–4 weeks
Atrophy RiskLow to Moderate
Celestone Soluspan contains both a rapidly soluble fraction and a more slowly absorbed depot fraction. This creates a dual-phase profile with relatively fast onset and sustained local effect. Some clinicians like this profile when both early relief and longer persistence are desired, though it is not universally necessary.
Corticosteroid Comparison at a Glance
Feature
TriamcinoloneMethylpred.DexamethasoneBetamethasone
Relative Potency
5x
5x
25x
25x
Formulation
Insoluble depot
Insoluble depot
Soluble
Dual (soluble + depot)
Onset
24–48 hrs
24–48 hrs
1–3 hrs
1–3 hrs (fast fraction)
Duration
2–6 weeks
2–4 weeks
3–7 days
2–4 weeks
Atrophy Risk
Moderate–High
Moderate
Low
Low–Moderate
Best Use Case
Deep muscle trigger point, standard corticosteroid trigger point injection
General trigger point injection, alternative to triamcinolone
Superficial or cosmetic areas
When rapid onset plus longer local effect is desired
§ 04
Injection Technique
Injection Technique
Step-by-Step IllustrationPatient Assessment & Trigger Point Identification
The clinician performs systematic palpation to identify active myofascial trigger points within taut bands. Each target is localized by finding the most tender nodule, looking for a local twitch response when present, and determining whether palpation reproduces the patient’s familiar referred pain pattern. The number of points to inject is then decided based on the clinical picture and the total steroid dose being considered.
Drug Selection & Preparation
The corticosteroid is selected based on trigger point depth, proximity to skin, local atrophy concerns, and desired duration of effect. Many practitioners dilute the steroid with 1% lidocaine (without epinephrine) to increase volume and provide immediate anesthetic relief. A common mixture is a small volume of corticosteroid combined with 1 to 2 mL of lidocaine, though exact practice varies.
Needle Selection & Skin Preparation
A 25 to 27 gauge needle is often selected. Needle length depends on muscle depth: shorter for superficial muscles and longer for deeper muscles. The site is prepared with chlorhexidine or alcohol using sterile technique. Some clinicians use topical anesthetic spray or topical lidocaine to reduce insertion discomfort.
Injection Technique
The trigger point is stabilized with pincer or flat palpation. The needle is advanced into the target area, and a local twitch response may help confirm contact with the trigger point when it occurs. After aspiration to reduce intravascular risk, the solution is injected slowly into the target. Some clinicians use a fanning technique to distribute the injectate across the taut band.
Ultrasound Guidance (When Indicated)
For deep trigger points, difficult anatomy, or muscles near important neurovascular structures, ultrasound guidance may be useful. It can improve confidence in needle placement and help avoid nearby critical structures. This is particularly relevant for deeper muscles or patients with more complex body habitus.
Post-Injection Care
Firm pressure is applied to the site for hemostasis. The patient is then observed briefly for immediate reaction. Post-procedure instructions usually include avoiding strenuous use of the injected region for 24 to 48 hours, using ice if soreness develops, and beginning gentle stretching afterward if appropriate. Patients should also be warned that a transient post-injection flare may occur before the anti-inflammatory effect becomes noticeable.
§ 05
Evidence for myofascial pain
Moderate EvidenceMixed results vs lidocaine alone
The evidence base for corticosteroid trigger point injection is moderate but mixed. Several randomized trials have compared steroid-containing injections with lidocaine alone and with dry needling, with inconsistent results regarding the added value of the corticosteroid component. A common interpretation is that the mechanical disruption of the trigger point may be very important, while corticosteroids may add value in more inflammatory presentations.
Frost et al. (1980)
A randomized double-blind trial in The Lancet compared mepivacaine injection with saline injection for myofascial pain. Both groups improved, and the saline group tended to have somewhat more pain relief after the first injection. This early result is often cited to suggest that the mechanical effect of needle insertion at the trigger point may matter at least as much as the specific injectate.
Hopwood & Abram (1994)
A prospective analysis of trigger point injection outcomes in chronic myofascial pain identified factors associated with treatment failure — including longer pain duration, higher pain intensity at baseline, and unemployment due to pain. The study highlighted that injection response is multifactorial rather than driven by injectate alone.
Trigger point injection literature (general)
Comparative studies of corticosteroid-containing versus anesthetic-only trigger point injections have produced mixed results. Some studies suggest a modest additional benefit when an inflammatory component is present, while others find no clear advantage over local anesthetic or dry needling alone. Sample sizes and study design limitations should be considered when interpreting these findings.
Borg-Stein & Simons (2002) — Review
This review concluded that adding corticosteroid to trigger point injection may provide modest additional benefit over anesthetic alone in selected cases, but that the evidence does not support routine steroid use in all trigger point injections because local tissue risks accumulate with repetition.
§ 06
Corticosteroid Trigger Point Injection vs Other Interventions
Feature
CorticosteroidLidocaine Trigger Point InjectionDry NeedlingPRPBOTOX
Mechanism
Anti-inflammatory + mechanical disruption of trigger point
Sodium channel blockade + mechanical disruption
Mechanical disruption + neurophysiological modulation
Growth factor-mediated tissue response
Chemical denervation via ACh blockade
Onset of Action
1–3 days
Immediate (1–2 minutes)
Immediate to 24–48 hours
2–4 weeks
2–7 days
Duration of Relief
2–6 weeks
Hours (anesthetic); sometimes longer therapeutic benefit
Days to weeks per session
3–6 months
3–6 months
Cost per Session
$100–300
$75–200
$50–150
$500–1,500
$500–1,500
Evidence Level
Moderate (mixed vs lidocaine alone)
Moderate to Strong clinical use base
Moderate to Strong
Emerging (limited RCTs)
Moderate (off-label)
Retreatment Limit
Often limited to 3–4x per year per site
No strict universal limit
No strict universal limit
No strict universal limit
Every 3 months minimum
Best For
Trigger points with possible inflammatory features
Pain requiring immediate local anesthetic relief
Common first-line interventional approach
Selected chronic refractory cases with tissue degeneration concerns
Selected chronic refractory cases with suspected motor endplate dysfunction
§ 07
Risks & Limitations
Critical SectionCumulative tissue damage limits repeat use
§ 08
Ideal Candidates & Contraindications
Ideal Candidates
Ideal Candidates & Contraindications
- Trigger Points with Apparent Local Inflammatory Features — Patients whose trigger points show more obvious local inflammatory features — such as warmth, tenderness with local tissue irritability, or reactive swelling — may be the best candidates for corticosteroid trigger point injection. In these cases the anti-inflammatory mechanism has the clearest rationale.
- Subacute Myofascial Pain Syndrome Unresponsive to Initial Conservative Care — Patients with myofascial pain lasting several weeks to a few months who have not responded adequately to physical therapy, stretching, NSAIDs, and other conservative treatment may be reasonable candidates for a steroid-based injection, especially if pain is limiting participation in rehabilitation.
- Trigger Points Contributing to Limited Range of Motion — When trigger point activity is contributing to significant motion loss because of pain and guarding, corticosteroid injection may help create a window in which mobility work and rehabilitation become easier to tolerate.
- Patients Who Responded Previously to Corticosteroid Trigger Point Injection — A clearly positive response to a previous corticosteroid trigger point injection suggests that repeat treatment may help again, provided frequency limits and tissue risks are respected.
- Patients with an Apparently Inflammatory Phenotype — Some patients seem to show a stronger inflammatory component — for example, more pronounced local flare response followed by meaningful relief. These cases may represent a better fit for corticosteroid use than non-inflammatory trigger points.
Absolute Contraindications
Relative Contraindications
Key Takeaways
Corticosteroids are synthetic glucocorticoid analogues with broad anti-inflammatory effects upstream of both the COX and LOX pathways.
Their use in trigger point injection is best understood as targeted and selective, not as a universal first-line injectate for every trigger point.
Triamcinolone acetonide is one of the most commonly used preparations, while dexamethasone may be preferred when lower atrophy risk matters more than depot duration.
The usual practical limit of 3 to 4 injections per site per year reflects concern about cumulative local tissue risk rather than a purely arbitrary rule.
Clinical evidence suggests corticosteroids may provide somewhat longer relief than anesthetic alone in selected trigger points with inflammatory features, but they are not clearly superior in every case.
Risks include local tissue atrophy, skin depigmentation, tendon weakening, blood glucose elevation, HPA axis suppression, and post-injection flare.
Ideal candidates are usually patients with selected inflamed or reactive trigger points that have not responded adequately to conservative treatment.
Corticosteroid trigger point injection is often best viewed as a bridge treatment — useful for reducing inflammation and pain enough to allow rehabilitation, while the broader perpetuating factors are addressed.
The Bottom Line
Corticosteroid trigger point injection is a potent but selective intervention within myofascial pain management. It is most useful when a trigger point appears to have a meaningful inflammatory component that is driving pain and dysfunction. The anti-inflammatory effect is broader than that of NSAIDs because corticosteroids act upstream of both the COX and LOX pathways. However, cumulative local tissue risk — including atrophy, fat necrosis, tendon weakening, and skin change — limits how often the treatment should be repeated. For that reason, corticosteroid trigger point injection is usually best viewed as a bridge therapy: a way to reduce pain and inflammation enough to create a rehabilitation window, while stretching, physical therapy, and correction of perpetuating factors are pursued.
Explore related deep dives:
Corticosteroid Injection Limits
Corticosteroid injections at the same trigger point site are usually limited because more frequent use raises the risk of atrophy, tendon weakening, skin change, and other local complications. Careful documentation of sites and dates matters.